| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01517165 Details | 2018-07-05 Interventional | 1 | 24 | Pioglitazone Opioid-Related … | - - | |||
| NCT01459679 Details | 2018-07-05 Interventional | 3 | 1721 | Ophthalmic Solu… Riboflavin Corneal Disease… Dilatation, Pat… Keratoconus Corneal Ectasia | - - | |||
| NCT01341496 Details | 2018-07-05 Interventional | 1 | 41 | Celecoxib Cyclophosphamid… Melanoma Neoplasms Sarcoma Epithelial Mali… Pleural Maligna… | - - | |||
| NCT01229644 Details | 2018-07-05 Interventional | 2 | 10 | Crenolanib Glioma | - - | |||
| NCT00005925 Details | 2018-07-05 Interventional | 1 | 3 | Muscimol Epilepsy | - - | |||
| NCT02403895 Details | 2018-07-03 Interventional | 2 | 11 | Paclitaxel Carcinoma, Non-… Lung Neoplasms Squamous Non Sm… | - Sponsor and Investigator decision was taken to terminate further recruitment into the study due to lack of observed responses rendering it futile to continue. As such, an abbreviated Clinical Study Report was produced based on data from 11 patients. | |||
| NCT01724619 Details | 2018-07-03 Interventional | 1 | 7 | Dihydrotestoste… Prostatic Neopl… Prostate Cancer | Study tracer can no longer be obtained at our institution - | |||
| NCT01135329 Details | 2018-07-03 Interventional | 2 | 15 | Busulfan Cyclophosphamid… Fludarabine Mycophenolic Ac… Tacrolimus Leukemia Lymphoma Myelodysplastic… Preleukemia Myelodysplastic… | The stopping rule was met and hence the study was closed - | |||
| NCT01059929 Details | 2018-07-03 Interventional | 4 | 41 | Dexmedetomidine Fentanyl Midazolam Propofol Critical Illnes… Mechanical Vent… | drug and placebo unavailable - | |||
| NCT02460016 Details | 2018-07-02 Interventional | 1 | 1 | Ziresovir Infections Respiratory Syn… Virus Diseases | We switched this study design to another study per IEC's recommendations. - | |||
| NCT02368197 Details | 2018-07-02 Interventional | 2/3 | 13 | Paclitaxel Constriction, P… Fistula Dialysis Access… | - - | |||
| NCT00845039 Details | 2018-07-02 Interventional | 2 | 4 | Antibodies, Mon… Cetuximab Irinotecan Colonic Neoplas… Rectal Neoplasm… Colon Cancer Rectal Cancer | Study terminated early 22Feb2010 with only 4 participants due to business reasons. Study terminated early 22Feb2010 with only 4 participants due to business reasons. Data were collected for too few participants to draw statistically meaningful conclusions and included concerns on participant confidentiality. | |||
| NCT00765375 Details | 2018-06-29 Interventional | 2 | 5 | Botulinum Toxin… Botulinum Toxin… abobotulinumtox… Acne Vulgaris | Investigator decision Study terminated after 5 subjects | |||
| NCT03506399 Details | 2018-06-28 Interventional | 1 | 0 | Contraceptive A… Contraceptives,… Estradiol Ethinyl Estradi… Levonorgestrel Healthy | Stopped for futility. Phase 3 studies not likely to meet primary endpoints. - | |||
| NCT01222871 Details | 2018-06-28 Interventional | 1/2 | 1 | Triamcinolone Nasal Polyps | not enough particpants - | |||
| NCT02862574 2016-000897-39 Details | 2018-06-27 Interventional | 2 | 15 | Methotrexate Tumor Necrosis … Arthritis Arthritis, Rheu… Necrosis Rheumatoid Arth… | Study was terminated by sponsor and decision was not due to any safety signals. Gilead decided to discontinue the development of andecaliximab in RA and this study was terminated. The decision was not due to any safety concerns. Because only 15 participants were enrolled, no formal statistical testing was completed. | |||
| NCT01579058 Details | 2018-06-27 Interventional | 4 | 20 | Bisoprolol Aortic Valve St… Constriction, P… Aortic Stenosis | The sponsor discontinued to support the study. - | |||
| NCT01050764 Details | 2018-06-27 Interventional | 1/2 | 10 | Antilymphocyte … Fludarabine Fludarabine pho… Melphalan Thiotepa Thymoglobulin Vidarabine Leukemia Leukemia, Lymph… Leukemia, Myelo… Leukemia, Myelo… Leukemia, Myelo… Lymphoma, Non-H… Myelodysplastic… Precursor Cell … Preleukemia Acute Lymphobla… Acute Myelogeno… Chronic Lymphoc… Chronic Myeloge… Leukemia, Acute Myelodysplastic… Non-Hodgkin Lym… | Safety - | |||
| NCT02413489 2014-005299-26 Details | 2018-06-26 Interventional | 2 | 36 | Daratumumab Lymphoma Lymphoma, Folli… Lymphoma, Large… Lymphoma, Mantl… Lymphoma, Non-H… | DLBCL and FL cohorts met the pre-specified futility criteria and will not proceed. The MCL
cohort was terminated due to slow recruitment and aggressive disease. The study was terminated due to 2 non-Hodgkin's lymphoma (NHL) sub types (DLBCL and FL cohorts) meeting the futility criteria defined in the protocol and the MCL cohort not having adequate recruitment. | |||
| NCT00543309 Details | 2018-06-25 Interventional | 2 | [1 Refs] | 106 | Milrinone Natriuretic Pep… Congenital Abno… Heart Defects, … | DSMB recommended termination based on interim outcomes analysis Single center design limits generalizability of findings. Study drug doses were extrapolated from published experience in other patient types. Study may have been underpowered to detect differences among treatment groups for secondary outcomes. |